Abstract
We present the case of an 8-year-old boy who developed common variable immunodeficiency (CVID) following rituximab therapy for the treatment of idiopathic thrombocytopenia (ITP). Since rituximab can cause prolonged hypogammaglobulinemia and increased susceptibility to infections, monitoring of immunoglobulin levels, antibody responses, B cells, and memory B cell subpopulations is recommended. This may be especially true when rituximab is used in the treatment of immune cytopenia such as ITP, which may occur in CVID.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
